Researchers conducted a retrospective cohort study using the Premier Research database of 175 U.S. hospitals. They included adult patients admitted with a culture-confirmed urinary tract infection, pneumonia or sepsis as principal diagnosis, or as a secondary diagnosis in the setting of respiratory failure. Enterobacteriaceae are common pathogens in pneumonia, sepsis and UTIs.
They defined inappropriate antimicrobial coverage as “failure to administer an antibiotic therapy in vitro active against the culture-confirmed pathogen within 2 days of admission.”
Among the 40,137 patients with Enterobacteriaceae infections who were studied, 4,984 received inappropriate antimicrobial coverage. CRE was more frequent in patients given inappropriate treatment than patients who received appropriate empiric therapy.
The proportions of total costs represented by antibiotics were similar in inappropriate treatment and appropriate empiric therapy groups. However, each additional day of inadequate therapy cost an additional $766 as compared to adequate treatment.
More articles on healthcare quality:
How hospitals in Southern California are helping patients affected by wildfires
3 quotes from Dr. Don Berwick on moral dilemmas facing modern physicians
Leapfrog: Chicago hospital’s lawsuit is ’11th hour gambit’ to change safety grade
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.